A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 135 participants.

Also called NCT07107945

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 135 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07107945
  • EU CT 2024-512577-27-00
  • WHO UTN U1111-1312-1389
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Canada, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Singapore, South Korea, Spain, Sweden, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07107945. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-09 (actual); primary completion 2027-04-16 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct07107945
Content hash
31fe576e20d2f88906a01b9233881c37f615a86ec56b5541e19d4abbe2173765